Elena Elimova, MD, discusses efficacy data for zanidatamab in HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.
Elena Elimova, MD
Advertisement
Elena Elimova, MD, is an Associate Professor, Department of Medicine, University of Toronto, Staff Medical Oncologist, Princess Margaret Hospital.
Articles by Elena Elimova, MD
Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.
Advertisement
Latest Updated Articles
Dr Elimova on the Efficacy of Zanidatamab With Chemotherapy in HER2+ Advanced/Metastatic Gastroesophageal AdenocarcinomaPublished: June 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5